Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals is poised for long-term success and growth, with promising treatments in the pipeline and expansion into new tissue types. Though there are risks and potential clinical issues, the company's strong financial model estimates a total firm value of $68 billion and a positive outlook. Recent changes, such as the extended patent expiry date for VYNDAMAX, have been factored into the model and could result in even higher valuation and market performance in the future.

Alnylam Pharmaceuticals is facing challenges with its RNAi therapeutics, particularly with its lead product Onpattro (patisiran) for the treatment of hATTR amyloidosis, as evidenced by the recent failure of the Phase 3 CARDIO-TTRansform trial and the subsequent increased estimates for competing products like AMVUTTRA (vutrisiran) and nucresiran. Management attributes the vulnerability of Onpattro to its trial design, which risks capturing too few accrued events in a rapidly-evolving ATTR-CM standard of care landscape, leaving the potential for limited market share for Onpattro and increased competition from other RNAi therapeutics like nucresiran. Further challenges include its limited pipeline products, increasing expenses, and strategic pillars to accelerate growth for its TTR franchise, which may not be enough to offset potential revenue losses.